News

News 27.08.2019 Research & Development: MP0250 (VEGF x HGF) in MM: PI Trial (in combination with Velcade®) – Encouraging responses observed in first patient cohorts triggered decision for further investment; IMiD Trial (in combination with Pomalyst®) – Start of phase 2 trial expected in Q4 19, having received FDA approval; MP0250 in...

External events
Event date: 19.09.2019 1-6h30 PM, Lausanne, Sept 19th 2019  Agora Centre, CHUV University Hospital https://www.swissbiotech.org/swiss-biotech-insight-20190919/ About the event This first in a series of Swiss Biotech Insight Events will address major clinical trial strategy challenges, while exploring exciting new solutions including real world data science, adaptive clinical trial design, biomarkers and more. Join us to hear from top experts from throughout the...

External events
Event date: 03.10.2019 1. Digital Health Lab Day - Life in numbers 5 on Thursday, October 3, 2019 in Wädenswil. ZHAW researchers and practitioners will present and discuss the latest trends and solutions in the field of Digital Health. The experts will also present specific tools for solving current challenges in thematic workshops. What...

News 20.08.2019 Schlieren (Zurich), Switzerland, August 20, 2019 – Kuros Biosciences, a leader in next generation bone graft technologies, today reported its results for the first half year 2019. The Company accelerated product sales in the first half of 2019, while further decreasing administrative expenses, confirming its successful transition into a full-fledged...

News 25.07.2019 Zurich, Switzerland and Rockville, MD, July 24, 2019 -- Neurimmune AG, a leading clinical-stage Swiss biotech company translating human immune memory into antibody therapeutics and REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV®...